

Michael S Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2736906/publications.pdf>

Version: 2024-02-01

124
papers

2,397
citations

218677

26
h-index

233421

45
g-index

125
all docs

125
docs citations

125
times ranked

2427
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Coronary Artery Bypass Surgery With Percutaneous Coronary Intervention With Drug-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 864-870.	2.8	303
2	Stent fracture associated with drug-eluting stents: Clinical characteristics and implications. Catheterization and Cardiovascular Interventions, 2007, 69, 387-394.	1.7	160
3	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thrombosis and Haemostasis, 2019, 119, 149-162.	3.4	107
4	Myocardial Bridging: An Up-to-Date Review. Journal of Invasive Cardiology, 2015, 27, 521-8.	0.4	95
5	Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheterization and Cardiovascular Interventions, 2005, 66, 507-511.	1.7	83
6	Cardiovascular Complications of Radiotherapy. American Journal of Cardiology, 2013, 112, 1688-1696.	1.6	82
7	Orbital atherectomy for treating de novo , severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial. Cardiovascular Revascularization Medicine, 2017, 18, 261-264.	0.8	71
8	Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 791-795.	2.9	63
9	Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. International Journal of Cardiology, 2007, 123, 34-42.	1.7	58
10	Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. Expert Review of Medical Devices, 2017, 14, 867-879.	2.8	58
11	Comparison of Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy. JACC: Cardiovascular Interventions, 2008, 1, 710-715.	2.9	57
12	Outcome After Surgery and Percutaneous Intervention for Cardiogenic Shock and Left Main Disease. Annals of Thoracic Surgery, 2008, 86, 29-34.	1.3	55
13	Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results) Tj ETQq1 1 0.784314 rgBT /Overloc	1.6	55
14	Meta-Analysis of Clinical Studies Comparing Coronary Artery Bypass Grafting With Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Unprotected Left Main Coronary Artery Narrowings. American Journal of Cardiology, 2010, 105, 1070-1075.	1.6	51
15	Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. Journal of Pathology, 2004, 203, 861-870.	4.5	50
16	Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel-eluting stents: Two-year clinical outcomes of paclitaxel-eluting stents in patients from the <sc>ARRIVE</sc> program. Catheterization and Cardiovascular Interventions, 2016, 88, 891-897.	1.7	50
17	Comparison by Meta-Analysis of Drug-Eluting Stents and Bare Metal Stents for Saphenous Vein Graft Intervention. American Journal of Cardiology, 2010, 105, 1076-1082.	1.6	49
18	Meta-Analysis of Studies Comparing Coronary Artery Bypass Grafting With Drug-Eluting Stenting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. American Journal of Cardiology, 2010, 105, 1540-1544.	1.6	47

#	ARTICLE	IF	CITATIONS
19	Real-World Multicenter Registry of Patients with Severe Coronary Artery Calcification Undergoing Orbital Atherectomy. <i>Journal of Interventional Cardiology</i> , 2016, 29, 357-362.	1.2	41
20	The Impact and Pathophysiologic Consequences of Coronary Artery Calcium Deposition in Percutaneous Coronary Interventions. <i>Journal of Invasive Cardiology</i> , 2016, 28, 160-7.	0.4	41
21	Minimizing femoral artery access complications during percutaneous coronary intervention: A comprehensive review. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 62-69.	1.7	39
22	Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 15-21.	1.7	37
23	In-stent Restenosis. <i>Interventional Cardiology Clinics</i> , 2016, 5, 211-220.	0.4	37
24	Cardiac allograft vasculopathy: A review. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E527-E536.	1.7	33
25	Comparison of Rotational Atherectomy Versus Orbital Atherectomy for the Treatment of Heavily Calcified Coronary Plaques. <i>American Journal of Cardiology</i> , 2017, 119, 1320-1323.	1.6	29
26	Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 369-377.	1.7	27
27	Orbital and rotational atherectomy during percutaneous coronary intervention for coronary artery calcification. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 61-67.	1.7	26
28	Cutting balloon angioplasty. <i>Journal of Invasive Cardiology</i> , 2002, 14, 552-6.	0.4	21
29	Outcomes of patients with severely calcified aorto-ostial coronary lesions who underwent orbital atherectomy. <i>Journal of Interventional Cardiology</i> , 2018, 31, 15-20.	1.2	19
30	Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 378-382.	2.9	18
31	Outcomes of nonagenarians who undergo percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 526-530.	1.7	17
32	Pooled Analysis of the CONFIRM Registries. <i>Journal of Endovascular Therapy</i> , 2015, 22, 57-62.	1.5	17
33	Comparison of Sirolimus-Eluting Stents With Paclitaxel-Eluting Stents in Saphenous Vein Graft Intervention (from a Multicenter Southern California Registry). <i>American Journal of Cardiology</i> , 2010, 106, 337-341.	1.6	16
34	Lower extremity revascularization via endovascular and surgical approaches: A systematic review with emphasis on combined inflow and outflow revascularization. <i>SAGE Open Medicine</i> , 2020, 8, 205031212092923.	1.8	16
35	Coronary Artery Perforation Following Percutaneous Coronary Intervention. <i>Journal of Invasive Cardiology</i> , 2016, 28, 122-31.	0.4	16
36	Adoption of Routine Ultrasound Guidance for Femoral Arterial Access for Cardiac Catheterization. <i>Journal of Invasive Cardiology</i> , 2016, 28, 311-4.	0.4	16

#	ARTICLE	IF	CITATIONS
37	Percutaneous coronary intervention for acute myocardial infarction due to unprotected left main coronary artery occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 416-420.	1.7	15
38	Role of Percutaneous Coronary Intervention in the Treatment of Cardiac Allograft Vasculopathy. <i>American Journal of Cardiology</i> , 2018, 121, 1051-1055.	1.6	15
39	Impact of diabetes and acute coronary syndrome on survival in patients treated with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 909-914.	1.7	14
40	Predictors and Long-Term Clinical Outcome of Longitudinal Stent Deformation. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	14
41	Current State of the Art in Approaches to Saphenous Vein Graft Interventions. <i>Interventional Cardiology Review</i> , 2017, 12, 85.	1.6	14
42	Long-Term Outcomes of Heart Transplantation Recipients With Transplant Coronary Artery Disease Who Develop In-Stent Restenosis After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 1729-1732.	1.6	13
43	Meta-Analysis of Randomized Trials of Postconditioning in ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 114, 946-952.	1.6	13
44	Impact of lesion location on procedural and acute angiographic outcomes in patients with critical limb ischemia treated for peripheral artery disease with orbital atherectomy: A CONFIRM registries subanalysis. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 440-445.	1.7	13
45	Outcomes in Elderly Patients With Severely Calcified Coronary Lesions Undergoing Orbital Atherectomy. <i>Journal of Interventional Cardiology</i> , 2017, 30, 134-138.	1.2	13
46	Acute procedural outcomes of orbital atherectomy for the treatment of common femoral artery disease: Sub-analysis of the CONFIRM Registries. <i>Vascular Medicine</i> , 2017, 22, 301-306.	1.5	12
47	Utilizing intravascular ultrasound imaging prior to treatment of severely calcified coronary lesions with orbital atherectomy: An ORBIT II sub-analysis. <i>Journal of Interventional Cardiology</i> , 2017, 30, 570-576.	1.2	12
48	Long-Term Outcomes After Percutaneous Coronary Intervention of Left Main Coronary Artery for Treatment of Cardiac Allograft Vasculopathy After Orthotopic Heart Transplantation. <i>American Journal of Cardiology</i> , 2010, 106, 1086-1089.	1.6	11
49	Pooled Analysis of the CONFIRM Registries: Safety Outcomes in Diabetic Patients Treated With Orbital Atherectomy for Peripheral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2014, 21, 258-265.	1.5	11
50	Gender differences in acute and 30-day outcomes after orbital atherectomy treatment of <i>de novo</i> , severely calcified coronary lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 671-677.	1.7	11
51	Orbital Atherectomy. <i>Interventional Cardiology Clinics</i> , 2019, 8, 161-171.	0.4	11
52	Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2699.	2.4	11
53	Assessment of Sex Differences in 5-Year Clinical Outcomes Following Endovascular Revascularization for Peripheral Artery Disease. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 110-115.	0.8	10
54	Orbital atherectomy treatment of severely calcified coronary lesions in patients with impaired left ventricular ejection fraction: one-year outcomes from the ORBIT II study. <i>EuroIntervention</i> , 2017, 13, 329-337.	3.2	10

#	ARTICLE	IF	CITATIONS
55	Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug-eluting stents: A multicenter Southern Californian Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 272-278.	1.7	9
56	Acute procedural outcomes of orbital atherectomy for the treatment of iliac artery disease: Sub-analysis of the CONFIRM registries. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 503-505.	0.8	9
57	A Review of Antithrombotic Treatment in Critical Limb Ischemia After Endovascular Intervention. <i>Cardiology and Therapy</i> , 2019, 8, 193-209.	2.6	9
58	Outcomes in Diabetic Patients Undergoing Orbital Atherectomy System. <i>Journal of Interventional Cardiology</i> , 2016, 29, 491-495.	1.2	8
59	Impact of diabetes mellitus on procedural and one year clinical outcomes following treatment of severely calcified coronary lesions with the orbital atherectomy system: A subanalysis of the ORBIT II study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1018-1025.	1.7	8
60	Cardiac allograft vasculopathy. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 143-52.	1.4	8
61	Percutaneous Coronary Intervention in Severely Calcified Unprotected Left Main Coronary Artery Disease: Initial Experience With Orbital Atherectomy. <i>Journal of Invasive Cardiology</i> , 2016, 28, 147-50.	0.4	8
62	ORBIT II sub-analysis: Impact of impaired renal function following treatment of severely calcified coronary lesions with the Orbital Atherectomy System. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 841-848.	1.7	7
63	Orbital Atherectomy for Treatment of Severely Calcified Coronary Artery Bifurcation Lesions: A Multicenter Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 34-38.	0.8	7
64	Low-dose Heparin for Elective Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2014, 27, 58-62.	1.2	6
65	Characterization of Cardiac Troponin Elevation in the Setting of Pediatric Supraventricular Tachycardia. <i>Pediatric Cardiology</i> , 2016, 37, 392-398.	1.3	6
66	Impact of diabetes mellitus on 5-year clinical outcomes following successful endovascular revascularization for peripheral artery disease. <i>Vascular Medicine</i> , 2020, 25, 33-40.	1.5	6
67	The role of extracorporeal membrane oxygenation in emergent percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock and cardiac arrest. <i>Journal of Invasive Cardiology</i> , 2008, 20, E269-72.	0.4	6
68	Multicenter Registry of Real-World Patients With Severely Calcified Coronary Lesions Undergoing Orbital Atherectomy: 1-Year Outcomes. <i>Journal of Invasive Cardiology</i> , 2018, 30, 121-124.	0.4	6
69	Safety of orbital atherectomy in patients with left ventricular systolic dysfunction. <i>Journal of Interventional Cardiology</i> , 2017, 30, 415-420.	1.2	5
70	Diagnostic Yield of Coronary Angiography in Asymptomatic Orthotopic Liver Transplantation Candidates. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 59-63.	0.8	5
71	Impact of Advanced Age on Procedural and Acute Angiographic Outcomes in Patients Treated for Peripheral Artery Disease With Orbital Atherectomy: A CONFIRM Registries Subanalysis. <i>Journal of Invasive Cardiology</i> , 2015, 27, 381-6.	0.4	5
72	Novel Technique of Advancing the Rotational Atherectomy Device: "Single-Operator" Technique. <i>Journal of Invasive Cardiology</i> , 2016, 28, 183-6.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Percutaneous Coronary Intervention for Coronary Bifurcation Lesions. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, 59-66.	1.4	5
74	Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 945-951.	1.7	4
75	Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study. <i>International Journal of Cardiology</i> , 2016, 222, 639-644.	1.7	4
76	Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy : from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial. <i>American Journal of Cardiology</i> , 2017, 119, 991-995.	1.6	4
77	Safety of Same-Day Discharge after Percutaneous Coronary Intervention with Orbital Atherectomy. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 573-576.	0.8	4
78	Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). <i>International Journal of Cardiology</i> , 2020, 305, 11-17.	1.7	4
79	Long-term outcomes of percutaneous coronary intervention in transplant coronary artery disease in pediatric heart transplant recipients. <i>Journal of Invasive Cardiology</i> , 2012, 24, 278-81.	0.4	4
80	Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. <i>Journal of Invasive Cardiology</i> , 2014, 26, 420-6.	0.4	4
81	Acute Procedural Outcomes of Orbital Atherectomy for the Treatment of Profunda Femoris Artery Disease: Subanalysis of the CONFIRM Registries. <i>Journal of Invasive Cardiology</i> , 2018, 30, 177-181.	0.4	4
82	Impact of the Use of Intravascular Imaging on Patients Who Underwent Orbital Atherectomy. <i>Journal of Invasive Cardiology</i> , 2018, 30, 77-80.	0.4	4
83	Orbital Atherectomy of Severely Calcified Unprotected Left Main Coronary Artery Disease: One-Year Outcomes. <i>Journal of Invasive Cardiology</i> , 2018, 30, 270-274.	0.4	4
84	Achieving Safe Femoral Arterial Access. <i>Current Cardiology Reports</i> , 2015, 17, 44.	2.9	3
85	Outcomes of patients with myocardial infarction who underwent orbital atherectomy for severely calcified lesions. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 497-500.	0.8	3
86	The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. <i>Korean Circulation Journal</i> , 2019, 49, 645.	1.9	3
87	Long-term outcomes of peripheral arterial disease patients with significant coronary artery disease undergoing percutaneous coronary intervention. <i>PLoS ONE</i> , 2021, 16, e0251542.	2.5	3
88	Incidence of Bradycardia and Outcomes of Patients Who Underwent Orbital Atherectomy Without a Temporary Pacemaker. <i>Journal of Invasive Cardiology</i> , 2017, 29, 59-62.	0.4	3
89	Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014, 22, 7.	0.0	2
90	Procedural and Long-Term Ischemic Outcomes of Tight Subtotal Occlusions Treated with Orbital Atherectomy: An ORBIT II Subanalysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 563-568.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Fractional Flow Reserve and Intravascular Ultrasound of Coronary Artery Lesions Beyond the Left Main: A Review of Literature. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 1-11.	1.4	2
92	Fractional Flow Reserve in End-Stage Liver Disease. <i>American Journal of Cardiology</i> , 2022, 166, 122-126.	1.6	2
93	Outcomes After Orbital Atherectomy of Severely Calcified Left Main Lesions: Analysis of the ORBIT II Study. <i>Journal of Invasive Cardiology</i> , 2016, 28, 364-9.	0.4	2
94	Gender-Based Differences in Outcomes After Orbital Atherectomy for the Treatment of De Novo Severely Calcified Coronary Lesions. <i>Journal of Invasive Cardiology</i> , 2016, 28, 440-443.	0.4	2
95	Impact of Impaired Renal Function in Patients With Severely Calcified Coronary Lesions Treated With Orbital Atherectomy. <i>Journal of Invasive Cardiology</i> , 2017, 29, 203-206.	0.4	2
96	"Single-Operator" Technique for Advancing the Orbital Atherectomy Device. <i>Journal of Invasive Cardiology</i> , 2017, 29, 92-95.	0.4	2
97	One-Year Outcomes of Orbital Atherectomy of Long, Diffusely Calcified Coronary Artery Lesions. <i>Journal of Invasive Cardiology</i> , 2018, 30, 230-233.	0.4	2
98	Bleeding Complications Before Angiography in Non- σ ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2619-2621.	2.8	1
99	Impact of age following treatment of severely calcified coronary lesions with the orbital atherectomy system: 3-year follow-up. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 655-659.	0.8	1
100	Orbital atherectomy treatment of severely calcified native coronary lesions in patients with prior coronary artery bypass grafting: Acute and one-year outcomes from the ORBIT II trial. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 498-502.	0.8	1
101	Orbital atherectomy for the treatment of small (2.5 mm) severely calcified coronary lesions: ORBIT II sub-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 268-272.	0.8	1
102	Common Carotid Filter. <i>Journal of the American College of Cardiology</i> , 2019, 74, 840-841.	2.8	1
103	Direct Stenting in Patients Treated with Orbital Atherectomy: An ORBIT II Subanalysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 454-460.	0.8	1
104	Percutaneous Coronary Intervention With an Initial Bolus of Low-Dose Heparin in Biomarker-Negative Patients. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 38-41.	0.8	1
105	Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. <i>EuroIntervention</i> , 2011, 7, 314-322.	3.2	1
106	The Impact of Antithrombotic Regimens on Clinical Outcomes After Endovascular Intervention and Bypass Surgery for Infrapopliteal Artery Disease. <i>Cardiology Research</i> , 2019, 10, 255-267.	1.1	1
107	Percutaneous revascularization for left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2012, 13, e32-6.	1.4	1
108	Pooled analysis of the CONFIRM Registries: outcomes in renal disease patients treated for peripheral arterial disease using orbital atherectomy. <i>Journal of Invasive Cardiology</i> , 2014, 26, 350-4.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Outcomes of Patients With a History of Coronary Artery Bypass Grafting Who Underwent Orbital Atherectomy for Severe Coronary Artery Calcification. <i>Journal of Invasive Cardiology</i> , 2017, 29, 359-362.	0.4	1
110	Outcomes of Orbital Atherectomy in Severely Calcified Small (2.5 mm) Coronary Artery Vessels. <i>Journal of Invasive Cardiology</i> , 2018, 30, 310-314.	0.4	1
111	Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention. <i>Journal of the Saudi Heart Association</i> , 2013, 25, 75-78.	0.4	0
112	Is Heparin an Acceptable Anticoagulant When Glycoprotein IIb/IIIa Inhibitors Are Not Used?. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 223-224.	2.9	0
113	The New Era of Interventional Cardiology: Tackling Complex Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2016, 5, xi.	0.4	0
114	Coronary Orbital Atherectomy. , 2018, , 681-698.		0
115	A randomized comparison of estimated radiation exposure between Low and conventional dose protocol during invasive coronary angiography (ERICA trial): Pilot study. <i>European Journal of Radiology</i> , 2020, 129, 109120.	2.6	0
116	A relationship between unrecognized anaemia and the development of type 2 diabetes mellitus in patient with cardiovascular risks. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 455-462.	1.9	0
117	Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry. <i>Cardiovascular Revascularization Medicine</i> , 2021, 32, 43-49.	0.8	0
118	Bivalirudin in acute coronary syndromes and percutaneous coronary intervention. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 3, S27-34.	1.4	0
119	Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents. <i>Journal of Invasive Cardiology</i> , 2012, 24, 316-9.	0.4	0
120	The use of percutaneous left ventricular assist device in high-risk percutaneous coronary intervention and cardiogenic shock. <i>Reviews in Cardiovascular Medicine</i> , 2013, 14, e144-9.	1.4	0
121	Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy. <i>Journal of Invasive Cardiology</i> , 2017, 29, 397-400.	0.4	0
122	Four-Year Outcomes of Multivessel Percutaneous Coronary Intervention With Xience V Everolimus-Eluting Stents. <i>Journal of Invasive Cardiology</i> , 2019, 31, 240-246.	0.4	0
123	Initial Experience With GlideAssist to Facilitate Advancement of Orbital Atherectomy Prior to Plaque Modification of Severely Calcified Coronary Artery Lesions. <i>Journal of Invasive Cardiology</i> , 2019, 31, 331-334.	0.4	0
124	Impact of Sex on Outcomes Among Patients With Cardiac Allograft Vasculopathy Who Undergo Percutaneous Coronary Intervention. <i>Journal of Invasive Cardiology</i> , 2020, 32, 453-458.	0.4	0